KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to -$10.8 million.

  • Jazz Pharmaceuticals' Cash from Financing Activities fell 10439.44% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$957.1 million, marking a year-over-year decrease of 123831.36%. This contributed to the annual value of $20.5 million for FY2024, which is 10672.1% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Cash from Financing Activities of -$10.8 million as of Q3 2025, which was down 10439.44% from -$124.5 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash from Financing Activities peaked at $4.7 billion during Q2 2021, and registered a low of -$813.5 million during Q1 2025.
  • For the 5-year period, Jazz Pharmaceuticals' Cash from Financing Activities averaged around $116.2 million, with its median value being -$78.5 million (2023).
  • Over the last 5 years, Jazz Pharmaceuticals' Cash from Financing Activities had its largest YoY gain of 62588.16% in 2021, and its largest YoY loss of 195323.53% in 2021.
  • Jazz Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$246.6 million in 2021, then skyrocketed by 107.95% to $19.6 million in 2022, then tumbled by 611.87% to -$100.3 million in 2023, then skyrocketed by 91.75% to -$8.3 million in 2024, then plummeted by 30.86% to -$10.8 million in 2025.
  • Its last three reported values are -$10.8 million in Q3 2025, -$124.5 million for Q2 2025, and -$813.5 million during Q1 2025.